Media.Player

ROLE OF ANTI-GALECTIN-1 ANTIBODIES IN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AND HYPOXIA ASSOCIATED ANGIOGENESIS DISORDERS

Technology Benefits

Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders

Technology Application

Anti-Gall monoclonal antibodies can be used in diagnosing, prognosing, monitoring, treating and/or modulating PTLD, including EBV-associated PTLD and/or hypoxia associated angiogenesis disorders.

Detailed Technology Description

The present invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD, and hypoxia associated angiogenesis disorders, using novel anti-Galectin-1 (anti-Gall) monoclonal antibodies. Gal1 is a member of a highly-conserved family of animal lectins that is expressed and secreted by a variety of tumors where it contributes to malignant transformation and metastasis. Targeted disruption of Gall-glycan interactions, through Gall blockade or prevention of N-glycan branching, attenuates hypoxia-driven angiogenesis, while promoting extensive remodeling of vascular networks and increased influx and expansion of immune effector cells into the tumor parenchyma. The presence or levels of Gall polypeptide can be determined by kits involving the use of anti-Gall monoclonal antibodies and the complex detected in the form of an ELISA or radioimmune assay (RIA).The method includes providing a biological sample comprising whole blood fluid, serum fluid, plasma fluid, interstitial fluid, cerebrospinal fluid, lymph fluid, saliva, stool, and urine. The invention also features a pharmaceutical composition comprising the antibody or antigen-binding fragment in a pharmaceutically acceptable carrier.

Supplementary Information

Inventor: SHIPP, Margaret, A. | OUYANG, Jing | TAKEYAMA, Kunihiko | KUTOK, Jeffery L. | RODIG, Scott J. | RABINOVICH, Gabriel | RUSSO, Diego, Omar, Croci | SALATINO, Mariana
Priority Number: WO2011060272A3
IPC Current: C07K001618 | A61K0039395 | C07K001646 | C12N001513 | G01N0033577
Title: COMPOSITIONS, KITS, AND METHODS FOR THE DIAGNOSIS, PROGNOSIS, MONITORING, TREATMENT AND MODULATION OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AND HYPOXIA ASSOCIATED ANGIOGENESIS DISORDERS USING GALECTIN-1 | COMPOSITIONS, KITS ET MÉTHODES UTILISÉS PO
Usefulness: COMPOSITIONS, KITS, AND METHODS FOR THE DIAGNOSIS, PROGNOSIS, MONITORING, TREATMENT AND MODULATION OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AND HYPOXIA ASSOCIATED ANGIOGENESIS DISORDERS USING GALECTIN-1 | COMPOSITIONS, KITS ET MÉTHODES UTILISÉS POUR LE DIAGNOSTIC, LE PRONOSTIC, LA SURVEILLANCE, LE TRAITEMENT ET LA MODULATION DES LYMPHOPROLIFÉRATIONS APRÈS GREFFE D'ORGANE ET DE L'HYPOXIE ASSOCIÉE À L'ANGIOGENÈSE AU MOYEN DE LA GALECTINE-1
Summary: The antibody or its antigen-binding fragment is used in a composition for detecting the presence or level of a Gal1 polypeptide, monitoring the progression of a disease in a subject, predicting the clinical outcome of a subject afflicted with a disease, assessing the efficacy of a therapy for a disease in a subject, treating a subject afflicted with a disease, monitoring the progression of a viral-associated PTLD or hypoxia associated angiogenesis disorder in a subject, assessing the efficacy of a test compound for inhibiting a viral-associated PTLD or hypoxia associated angiogenesis disorder in a subject, predicting the clinical outcome of a subject afflicted with a viral-associated PTLD or hypoxia associated angiogenesis disorder, assessing the efficacy of a therapy for a viral-associated PTLD or hypoxia associated angiogenesis disorder in a subject, modulating an immune response in a subject afflicted with a viral-associated PTLD or hypoxia associated angiogenesis disorder, treating a subject afflicted with a viral-associated PTLD or hypoxia associated angiogenesis disorder, modulating angiogenesis in a hypoxia associated angiogenesis disorder, and identifying a compound that modulates a Gal1/VEGFR2 complex. The disease is a viral-associated PTLD, a cancer, and a hypoxia-associated related angiogenesis disorder (all claimed).
Novelty: New monoclonal antibody or its antigen-binding fragment comprises heavy and light chain sequences identical to anti-human galanin receptor 1 (Gal1) antibody, useful for treating cancer and hypoxia-associated related angiogenesis disorder

Industry

Disease Diagnostic/Treatment

Sub Category

Cancer/Tumor

*Abstract

The present invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD.

Country/Region

USA